Human IL-10 RB ELISA Kit (Interleukin-10 Receptor beta)
Cell culture supernatant, Serum, Plasma
< 5 pg/ml
4.12 pg/ml -
Cell culture supernatant
Multiple steps standard assay
Abcam’s IL-10 RB (Interleukin 10 Receptor beta) Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme linked immunosorbent assay for the quantitative measurement of Human IL-10 RB in serum, plasma, and cell culture supernatants.
This assay employs an antibody specific for Human IL-10 RB coated on a 96-well plate. Standards and samples are pipetted into the wells and IL-10 RB present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human IL-10 RB antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of IL-10 RB bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IL29.
Defects in IL10RB are the cause of inflammatory bowel disease type 25 (IBD25) [MIM:612567]. It is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
Belongs to the type II cytokine receptor family. Contains 2 fibronectin type-III domains.